Update on pharmacologic and nonpharmacologic therapies for smoking cessation

Canadian Family Physician

Volumn 54, Issue 7, 2008, Pages 994-999

  Schmelzle, Jason ^a   Rosser, Walter W ^a   Birtwhistle, Richard ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b Centre for Studies in Primary Care

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; PLACEBO; VARENICLINE;

ABSTINENCE; BEHAVIOR THERAPY; CANADA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; COUNSELING; DIZZINESS; DREAMING; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH PROGRAM; HICCUP; HUMAN; INSOMNIA; JAW DISEASE; MONOTHERAPY; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINORRHEA; SEIZURE; SELF HELP; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SMOKING HABIT; SNEEZING; SORE JAW; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; TREATMENT PLANNING; XEROSTOMIA;

CANADA; HUMANS; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 48349113093     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Health Canada. The national strategy: moving forward. The 2005 progress report on tobacco control. Ottawa, ON: Health Canada; 2005. Available from: www.hc-sc.gc.ca/hl-vs/alt_formats/hecs-sesc/pdf/pubs/tobac- tabac/foward-avant/foward-avant-eng.pdf. Accessed 2007 Aug 16.
2. Makomaski Illing EM, Kaiserman MJ. Mortality attributable to tobacco use in Canada and its regions, 1998. Can J Public Health 2004;95(1):38-44.
3. Health Canada. Canadian tobacco use monitoring survey (CTUMS) 2006. Summary of annual results for 2006. Ottawa, ON: Health Canada; 2007. Available from: www.hc-sc.gc.ca/hl-vs/tobac-tabac/research-recherche/stat/
4. Hughes JR, Gulliver SB, Fenwick JW, Valliere WA, Cruser K, Pepper S, et al. Smoking cessation among self-quitters. Health Psychol 1992;11(5):331-4.
5. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA 2000;283(24):3244-54.
6. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med 2003;18(12):1053-7.
7. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005;55(5):281-99.
8. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000146.
9. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;23(1):CD000146.
10. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;24(1):CD000031.
11. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):56-63.
12. McClure JB, Swan GE. Tailoring nicotine replacement therapy: rationale and potential approaches. CNS Drugs 2006;20(4):281-91.
13. Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002;62(Suppl 2):45-52.
14. Hays JT, Ebbert JO. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs 2003;17(2):71-83.
15. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-91.
16. Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract 2003;57(3):224-30.
17. Frishman WH, Mitta W, Kupersmith A, Ky T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev 2006;14(2):57-73.
18. Pfizer Canada Inc. Prescription medications: Champix. Kirkland, QC: Pfizer Canada Inc; 2007. Available from: www.pfizer.ca/english/ our%20products/prescription%20pharmaceuticals/default.asp?s=1. Accessed 2007 Aug 8.
19. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48(10):3474-7.
20. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166(15):1571-7.
21. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55.
22. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007;24(1):CD006103.
23. Sutherland G. Current approaches to the management of smoking cessation. Drugs 2002;62(Suppl 2):53-61.
24. Lancaster T, Stead LF. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004;18(4):CD000165.
25. Lancaster T, Stead LF. Individual behavioural counseling for smoking cessation. Cochrane Database Syst Rev 2005;18(2):CD001292.
26. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005;18(2):CD001007.
27. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev 2005;20(3):CD001118.
28. Stead LF, Perera R, Lancaster T. Telephone counseling for smoking cessation. Cochrane Database Syst Rev 2006;19(3):CD002850.
29. Swartz LH, Noell JW, Schroeder SW, Ary DV. A randomised control study of a fully automated internet based smoking cessation programme. Tob Control 2006;15(1):7-12.
30. Strecher VJ, Shiffman S, West R. Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction 2005;100(5):682-8.
31. Etter JF. Internet-based smoking cessation programs. Int J Med Inform 2006;75(1):110-6.
32. Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge A, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax 2003;58(6):484-8.
33. Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J. Intensive smoking cessation counselling versus minimal counselling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med 2003;114(7):555-62.
34. Macleod ZR, Charles MA, Arnaldi VC, Adams IM. Telephone counselling as an adjunct to nicotine patches in smoking cessation: a randomised controlled trial. Med J Aust 2003;179(7):349-52.
35. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading. BMJ 1999;318(7197):1548-51.
36. Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2002;2:1.
37. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297(11):1233-40.
38. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359(9308):781-5.
39. Strine TW, Okoro CA, Chapman DP, Balluz LS, Ford ES, Ajani UA, et al. Health related quality of life and health risk behaviors among smokers. Am J Prev Med 2005;28(2):182-7.
40. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in pharmacology. Biol Psychiatry 2006;59(11):1001-5.
41. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. BMJ 2006;332(7547):969-71.
42. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4.